Now just past the half way point of the research the RETHRIM project, funded through H2020, has been further developing an academic infrastructure for the harmonized production of MSC (Mesenchymal stromal cells).

The aim of the project was to conduct the first Europe-wide placebo controlled randomised phase III trial using MSC regenerative therapy for the treatment of steroid-resistant visceral GvHD (Graft-versus-Host-Disease). It has been co-ordinated at LUMC and hopes that the potential future commercialisation of the product may lead to greater benefits for patients suffering from disorders associated with tissue of organ injury.

Leave a Reply

Your email address will not be published. Required fields are marked *

Post comment